344 related articles for article (PubMed ID: 9676417)
1. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success.
Lebret T; Gaudez F; Hervé JM; Barré P; Lugagne PM; Botto H
Eur Urol; 1998; 34(1):67-72. PubMed ID: 9676417
[TBL] [Abstract][Full Text] [Related]
2. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
3. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
4. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
Eure GR; Cundiff MR; Schellhammer PF
J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
[TBL] [Abstract][Full Text] [Related]
6. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
7. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
8. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
Brake M; Loertzer H; Horsch R; Keller H
Urology; 2000 May; 55(5):673-8. PubMed ID: 10792077
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of superficial bladder cancer.
Amling CL
Curr Probl Cancer; 2001; 25(4):219-78. PubMed ID: 11514784
[TBL] [Abstract][Full Text] [Related]
11. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours.
Patard JJ; Rodriguez A; Leray E; Rioux-Leclercq N; Guillé F; Lobel B
Eur Urol; 2002 Jun; 41(6):635-41; discussion 642. PubMed ID: 12074781
[TBL] [Abstract][Full Text] [Related]
12. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer.
Matsumoto K; Kikuchi E; Shirakawa H; Hayakawa N; Tanaka N; Ninomiya A; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Dec; 110(11 Pt B):E508-13. PubMed ID: 22574662
[TBL] [Abstract][Full Text] [Related]
13. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
14. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A
Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120
[TBL] [Abstract][Full Text] [Related]
15. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
Peyromaure M; Zerbib M
BJU Int; 2004 Jan; 93(1):60-3. PubMed ID: 14678369
[TBL] [Abstract][Full Text] [Related]
16. [Role of BCG in T1G3 bladder transitional cell carcinoma (TCC): our experience].
Comeri GC; Belvisi P; Conti G; Cretarola E; Duvia R; Furgoni R; Gianneo E; Radice GP
Arch Ital Urol Androl; 1996 Feb; 68(1):55-9. PubMed ID: 8664924
[TBL] [Abstract][Full Text] [Related]
17. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
[TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
Andius P; Holmäng S
BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
[TBL] [Abstract][Full Text] [Related]
19. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG; Neulander E; Murphy WM; Wajsman Z
Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
[TBL] [Abstract][Full Text] [Related]
20. Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer.
Mack D; Frick J
Urology; 1995 Jun; 45(6):958-61. PubMed ID: 7771030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
